TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38697155

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (5·4 mg/kg intravenously once every 21 days)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Treatment of physician's choice (capecitabine, lapatinib, or trastuzumab)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 608

Group type: COMPARATOR
Intervention: Treatment of physician's choice
Number of subjects: 608
Study: 38697156

Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg) plus gemcitabine and cisplatin
Number of subjects: 685

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and cisplatin
Number of subjects: 685
Study: 38697182

Group type: EXPERIMENTAL
Intervention: AHCL therapy (MiniMed 780G)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard insulin therapy
Number of subjects: 95
Study: 38697184

Group type: EXPERIMENTAL
Intervention: Setmelanotide (3.0 mg, subcutaneously once a day for 16 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Historic control rate
Number of subjects: 18
Study: 38697216

Group type: EXPERIMENTAL
Intervention: Uniform Multidrug Therapy (U-MDT) for 6 months
Number of subjects: 613

Group type: COMPARATOR
Intervention: Regular Multidrug Therapy (R-MDT) for 12 months
Number of subjects: 613

Group type: COMPARATOR
Intervention: Comparison of U-MDT and R-MDT
Number of subjects: 613
Study: 38697235

Group type: COMPARATOR
Intervention: Colonoscopy only
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Active choice of colonoscopy or FIT
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: FIT only
Number of subjects: 738
Study: 38697286

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 426

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 426
Study: 38697618

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg by mouth twice daily and capecitabine 1000 mg/m2 by mouth twice daily
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nintedanib and capecitabine
Number of subjects: 42
Study: 38697677

Group type: EXPERIMENTAL
Intervention: 12 weeks of once-weekly online Singing for Lung Health (SLH) sessions
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 115
Study: 38697766

Group type: EXPERIMENTAL
Intervention: Hospital at home treatment
Number of subjects: 849
Study: 38697776

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided V2 and V3 combined nerves block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraoral infiltration of local anesthetic
Number of subjects: 50
Study: 38697821

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy using indocyanine green
Number of subjects: 100
Study: 38697873

Group type: EXPERIMENTAL
Intervention: Zuranolone
Number of subjects: 0
Study: 38698170

Group type: EXPERIMENTAL
Intervention: Encorafenib plus Binimetinib
Number of subjects: 0
Study: 38698175

Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 245

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 245
Study: 38698315

Group type: EXPERIMENTAL
Intervention: Trauma-focused psychotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-trauma-focused psychotherapy
Number of subjects: 0
Study: 38698355

Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) for 5 days per month for 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 100
Study: 38698396

Group type: EXPERIMENTAL
Intervention: 6 ml iPAAG injection
Number of subjects: 49
Study: 38698433

Group type: EXPERIMENTAL
Intervention: Active spinal manual therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo-control spinal manual therapy
Number of subjects: 60
Study: 38698442

Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day) added to standard enteral nutrition to achieve a high amount of enteral protein (2-2.4 g/kg/day)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: No supplemental enteral protein to achieve a moderate amount of enteral protein (0.8-1.2 g/kg/day)
Number of subjects: 2502

Group type: EXPERIMENTAL
Intervention: Supplemental enteral protein (1.2 g/kg/day)
Number of subjects: 2502

Group type: COMPARATOR
Intervention: No supplemental enteral protein
Number of subjects: 2502
Study: 38698471

Group type: EXPERIMENTAL
Intervention: Focused lung ultrasonography (FLUS) performed in addition to usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38698497

Group type: EXPERIMENTAL
Intervention: Hypertension training courses
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Surveys measuring adaptive reserve, evidence-based practice attitudes, and implementation leadership
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Interviews assessing facilitators and barriers to hypertension care delivery
Number of subjects: 124
Study: 38698639

Group type: EXPERIMENTAL
Intervention: DopaFuse therapy (continuous delivery of levodopa/carbidopa)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard oral levodopa/carbidopa administration
Number of subjects: 16
Study: 38698643

Group type: EXPERIMENTAL
Intervention: Transitional palliative care intervention (TPC) for FCGs, involving teaching, guidance, and counseling via video calls for 8 weeks after CR discharge.
Number of subjects: 282

Group type: COMPARATOR
Intervention: Attention control condition for FCGs.
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Transitional palliative care intervention (TPC) for FCGs.
Number of subjects: 282
Study: 38698931

Group type: EXPERIMENTAL
Intervention: Moving Together program (1 hour, 2 days/week, 12 weeks)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Moving Together program
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 97
Study: 38699307

Group type: EXPERIMENTAL
Intervention: Ixazomib, Lenalidomide, and Dexamethasone (IRD)
Number of subjects: 55
Study: 38699346

Group type: EXPERIMENTAL
Intervention: Combination treatment (duloxetine + web-based self-guided CBT) with phone-based motivational interviewing (MI)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Combination treatment without phone-based MI
Number of subjects: 280

Group type: COMPARATOR
Intervention: Duloxetine monotherapy
Number of subjects: 280
Study: 38699828

Group type: EXPERIMENTAL
Intervention: Amoxicillin and metronidazole
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin and metronidazole
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 38699939

Group type: EXPERIMENTAL
Intervention: Cedirogant 75 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cedirogant 150 mg
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Cedirogant 375 mg
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 38700040

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 787

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 787
Study: 38700045

Group type: COMPARATOR
Intervention: Antiviral medications (aciclovir, ganciclovir, valaciclovir)
Number of subjects: 5054

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 5054

Group type: COMPARATOR
Intervention: Extended duration prophylaxis
Number of subjects: 5054

Group type: COMPARATOR
Intervention: Maribavir
Number of subjects: 5054
Study: 38700322

Group type: EXPERIMENTAL
Intervention: Preprocedural sGFAP levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lower sGFAP levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Higher sNfL levels
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: sNfL-to-sGFAP ratio
Number of subjects: 38
Study: 38700557

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38700568

Group type: EXPERIMENTAL
Intervention: Preanesthesia teleconsultation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 38700579

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of rh-endostatin (210 mg) over a period of 120 hours combined with platinum-based doublet chemotherapy (pemetrexed or paclitaxel) in 21-day cycles.
Number of subjects: 48
Study: 38700601

Group type: EXPERIMENTAL
Intervention: Microvascular plugs (MVPs)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Platinum-fibered microcoils
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both MVPs and coils
Number of subjects: 60
Study: 38700630

Group type: EXPERIMENTAL
Intervention: 10-day bismuth-containing quadruple therapy
Number of subjects: 1300

Group type: COMPARATOR
Intervention: 14-day bismuth-containing quadruple therapy
Number of subjects: 1300
Study: 38700646

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg as monotherapy every 2 weeks for 16 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38700657

Group type: EXPERIMENTAL
Intervention: Patients with new-onset atrial fibrillation (NOAF)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: Higher CURB-65, PSI class, and CHA score in NOAF patients
Number of subjects: 473
Study: 38700656

Group type: EXPERIMENTAL
Intervention: Delta variant infection
Number of subjects: 758

Group type: COMPARATOR
Intervention: Omicron variant infection
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Overall patient cohort
Number of subjects: 758
Study: 38700708

Group type: EXPERIMENTAL
Intervention: Levomilnacipran Extended Release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38700808

Group type: EXPERIMENTAL
Intervention: Apitolisib (PI3K/mTOR inhibitor)
Number of subjects: 2
Study: 38700867

Group type: EXPERIMENTAL
Intervention: Therapist-supported, internet-delivered exposure and response prevention (ERP) for 10 weeks
Number of subjects: 221

Group type: COMPARATOR
Intervention: Therapist-supported, internet-delivered psychoeducation for 10 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Health economic evaluation of ERP
Number of subjects: 221

Group type: COMPARATOR
Intervention: Health economic evaluation of psychoeducation
Number of subjects: 221
Study: 38700862

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin transfusion threshold
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin transfusion threshold
Number of subjects: 1690

Group type: COMPARATOR
Intervention: Control periods (pretransfusion periods)
Number of subjects: 1690
Study: 38700928

Group type: EXPERIMENTAL
Intervention: Unconditional social transfer at 6 months post partum
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Social transfer at 6 months post partum conditional upon mothers exclusively breastfeeding
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Educational materials supporting mothers to exclusively breastfeed (provided to all groups)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group, no social transfer
Number of subjects: 300
Study: 38701074

Group type: EXPERIMENTAL
Intervention: eHealth intervention (#SafeHandsSafeHearts)
Number of subjects: 202
Study: 38701088

Group type: EXPERIMENTAL
Intervention: YANG NIR spectroscopy sensor (Indigo) implanted for 28 days
Number of subjects: 7
Study: 38701179

Group type: EXPERIMENTAL
Intervention: rSS = 0
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: 0 < rSS ≤ 8
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: rSS > 8
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Residual ischaemia (rSS)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Baseline SYNTAX score
Number of subjects: 408
Study: 38701390

Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance
Number of subjects: 435

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 435
Study: 38701435

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 3923

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3923
Study: 38701440

Group type: EXPERIMENTAL
Intervention: Web-based self-management program (Agir pour moi - APM)
Number of subjects: 63
Study: 38701490

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (home exercise, branched-chain amino acids, multistrain probiotic)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 32
Study: 38701812

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (17.5 ± 2.5 mg/kg per day for 6 months, followed by dose escalation up to 20-35 mg/kg per day)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Hydroxyurea dose escalation to MTD with dose optimisation
Number of subjects: 606
Study: 38701817

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 38701823

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 10259

Group type: COMPARATOR
Intervention: No nirsevimab
Number of subjects: 10259
Study: 38701878

Group type: EXPERIMENTAL
Intervention: MDD group
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: IL-10
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: BDNF
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study: 38701881

Group type: EXPERIMENTAL
Intervention: Withdrawing neurohormonal blockers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurohormonal blockers (control group)
Number of subjects: 0
Study: 38701961

Group type: EXPERIMENTAL
Intervention: Down Sizing Strategy (HANGZHOU Solution)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Annulus Sizing Strategy
Number of subjects: 0
Study: 38702085

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 0
Study: 38702342

Group type: EXPERIMENTAL
Intervention: EPA/AA ratio in Group 4
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: C-Reactive Protein
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interleukin-6
Number of subjects: 180
Study: 38702523

Group type: EXPERIMENTAL
Intervention: Systematic and equitable digital-health-team-based care program implementing tighter glucose targets (HbA1c < 7%), early technology use (continuous glucose monitoring starts <1 month after diagnosis), remote patient monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic and equitable digital-health-team-based care program
Number of subjects: 0
Study: 38702618

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with fever (ERMF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural analgesia without fever
Number of subjects: 60

Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 60
Study: 38702619

Group type: EXPERIMENTAL
Intervention: Standardized education and home blood pressure monitoring
Number of subjects: 250
Study: 38702654

Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) in low-risk group (≤ 1 risk factors)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) in high-risk group (> 1 risk factors)
Number of subjects: 274
Study: 38702744

Group type: EXPERIMENTAL
Intervention: Pre-placed bronchial balloon
Number of subjects: 250

Group type: COMPARATOR
Intervention: None-pre-placed bronchial balloon
Number of subjects: 250
Study: 38702751

Group type: EXPERIMENTAL
Intervention: Postpartum patient navigation program
Number of subjects: 11
Study: 38702761

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) 36.25 Gy in 5 fractions to the whole prostate gland with MRI guided simultaneous integrated focal boost (SIB) to the index lesion (IL) up to 50 Gy in 5 fractions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SABR with MRI guided focal dose intensification
Number of subjects: 0
Study: 38702783

Group type: EXPERIMENTAL
Intervention: Mind-body intervention as an adjunct to MOUD
Number of subjects: 303
Study: 38702786

Group type: EXPERIMENTAL
Intervention: Penalized semi-parametric mixture cure model (MCM) using RNA-sequencing data
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Training set MCM
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Test set MCM
Number of subjects: 346
Study: 38702828

Group type: EXPERIMENTAL
Intervention: Neoadjuvant niraparib treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant platinum-taxane doublet chemotherapy
Number of subjects: 0
Study: 38702961

Group type: EXPERIMENTAL
Intervention: Sodium channel blockers (SCBs) - flecainide or propafenone
Number of subjects: 1395
Study: 38703010

Group type: EXPERIMENTAL
Intervention: Nirogacestat (150 mg, twice-daily, continuous 28-day cycles)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Nirogacestat (150 mg)
Number of subjects: 73
Study: 38703071

Group type: EXPERIMENTAL
Intervention: METsmeasured
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: METsestimated
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: V˙O2Reserve
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Current classification metrics
Number of subjects: 98
Study: 38703097

Group type: EXPERIMENTAL
Intervention: Screening presented as an opportunity
Number of subjects: 790

Group type: COMPARATOR
Intervention: Screening presented as a choice
Number of subjects: 790

Group type: EXPERIMENTAL
Intervention: Screening presented as an opportunity plus a question about women's stage of decision making
Number of subjects: 790

Group type: COMPARATOR
Intervention: Usual care (no specific intervention)
Number of subjects: 790
Study: 38703149

Group type: EXPERIMENTAL
Intervention: JR-CTO score (moderate-severe calcification, tortuosity, Werner collateral connection grade ≤1, and nonseptal collateral channel)
Number of subjects: 2374

Group type: EXPERIMENTAL
Intervention: Lower JR-CTO scores
Number of subjects: 2374
Study: 38703279

Group type: EXPERIMENTAL
Intervention: NHFOV
Number of subjects: 100

Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 100
Study: 38703336

Group type: EXPERIMENTAL
Intervention: 300 mg AZD7442 (tixagevimab/cilgavimab) in PROVENT
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: 300 mg AZD7442 (tixagevimab/cilgavimab) in STORM CHASER
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo in PROVENT
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo in STORM CHASER
Number of subjects: 6000
Study: 38703375

Group type: EXPERIMENTAL
Intervention: Monomorphic ventricular tachycardia (MMVT)
Number of subjects: 2668

Group type: EXPERIMENTAL
Intervention: Polymorphic ventricular tachycardia (PVT)/ventricular fibrillation (VF)
Number of subjects: 2668

Group type: EXPERIMENTAL
Intervention: Competing risk Fine-Gray model for MMVT
Number of subjects: 2668
Study: 38703782

Group type: EXPERIMENTAL
Intervention: Inoculation with SARS-CoV-2 in a stepwise dose escalation controlled human infection model (CHIM) with a dose of 1×10
Number of subjects: 36
Study: 38703890

Group type: EXPERIMENTAL
Intervention: High Eating Frequency (6 eating occasions/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low Eating Frequency (3 eating occasions/d)
Number of subjects: 50
Study: 38703993

Group type: EXPERIMENTAL
Intervention: FDA-approved anti-angiogenic agents combined with immunotherapy and nanocarrier-mediated targeted therapy
Number of subjects: 0
Study: 38704119

Group type: EXPERIMENTAL
Intervention: Standard educational materials combined with web-based decision support tools
Number of subjects: 415

Group type: COMPARATOR
Intervention: Standard educational materials alone
Number of subjects: 415
Study: 38704288

Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: KardiaMobile 6L
Number of subjects: 98

Group type: COMPARATOR
Intervention: 12L-ECG
Number of subjects: 98
Study: 38704294

Group type: EXPERIMENTAL
Intervention: IRB/AML 150/5 mg
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: IRB/AML 150/10 mg
Number of subjects: 428

Group type: COMPARATOR
Intervention: IRB 150 mg/placebo
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: IRB/AML 300/5 mg
Number of subjects: 428

Group type: COMPARATOR
Intervention: IRB 300 mg/placebo
Number of subjects: 428
Study: 38704329

Group type: EXPERIMENTAL
Intervention: Self-Esteem Development Programme (8 sessions, 45-60 min each, one session per week)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Routine education programme (control group)
Number of subjects: 66
Study: 38704414

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training for twelve weeks (n=14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 30
Study: 38704501

Group type: EXPERIMENTAL
Intervention: melphalan/Hepatic Delivery System (melphalan/HDS)
Number of subjects: 91
Study: 38704628

Group type: EXPERIMENTAL
Intervention: Intraoperative frozen section analysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single-stage management with intraoperative frozen section analysis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single-stage management
Number of subjects: 37
Study: 38704836

Group type: EXPERIMENTAL
Intervention: Tension band fixation
Number of subjects: 122

Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 122
Study: 38704840

Group type: EXPERIMENTAL
Intervention: Nadofaragene firadenovec-vncg
Number of subjects: 151
Study: 38704861

Group type: EXPERIMENTAL
Intervention: RL-BAV with CoA
Number of subjects: 44

Group type: COMPARATOR
Intervention: BAV
Number of subjects: 44
Study: 38704973

Group type: EXPERIMENTAL
Intervention: Exposure-based treatment for perfectionism (ETP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Stress management treatment
Number of subjects: 85
Study: 38705160

Group type: EXPERIMENTAL
Intervention: Group A+I (ibrutinib combined with R-CHOP)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Group A (R-CHOP with ASCT)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Group I (ibrutinib only)
Number of subjects: 870

Group type: EXPERIMENTAL
Intervention: Group A+I (after ASCT)
Number of subjects: 870

Group type: COMPARATOR
Intervention: Group A (ASCT)
Number of subjects: 870
Study: 38705163

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine with primaquine (0.25 mg/kg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine with tafenoquine (1.66 mg/kg)
Number of subjects: 80